Think of biotech and the bioeconomy as a broad methodology encompassing all those who use and borrow from biology to produce ...

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ. The Philadelphia biotech’s ...

Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise. Bright Minds shares DRUG ...

Allison DeAngelis, who covers biotech startups and venture capital, is also the author of STAT’s annual report “Ranking Biotech’s Top Venture Capital Firms.” Biotech investors have been ...

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity. The ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...

Apr. 23, 2024 — Researchers describe the steps they took to manipulate DNA and proteins -- essential building blocks of life -- to create cells that look and act like cells from the body. This ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

Fidelity Select Biotechnology Portfolio earns an Above Average Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance ...